Ascent Wealth Partners’s Marker Therapeutics MRKR Stock Holding History

Ascent Wealth Partners’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,027	Closed	-$2.73K	–	150
2022 Q4	$2.73K	Buy	+1,027	New	+$3.54K	﹤0.01%	141
2022 Q2	–	Sell	-1,027	Closed	-$5K	–	150
2022 Q1	$5K	Hold	1,027	–	–	﹤0.01%	147
2021 Q4	$10K	Hold	1,027	–	–	﹤0.01%	145
2021 Q3	$17K	Hold	1,027	–	–	﹤0.01%	148
2021 Q2	$29K	Hold	1,027	–	–	0.01%	147
2021 Q1	$23K	Hold	1,027	–	–	0.01%	120
2020 Q4	$15K	Hold	1,027	–	–	﹤0.01%	115
2020 Q3	$15K	Hold	1,027	–	–	﹤0.01%	110
2020 Q2	$21K	Hold	1,027	–	–	0.01%	106
2020 Q1	$20K	Hold	1,027	–	–	0.01%	106
2019 Q4	$30K	Hold	1,027	–	–	0.01%	117
2019 Q3	$52K	Hold	1,027	–	–	0.02%	115
2019 Q2	$81K	Hold	1,027	–	–	0.03%	116
2019 Q1	$68K	Hold	1,027	–	–	0.02%	120
2018 Q4	$57K	Hold	1,027	–	–	0.02%	117
2018 Q3	$93K	Hold	1,027	–	–	0.03%	123
2018 Q2	$97K	Buy	+1,027	New	+$52.4K	0.03%	121

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascent Wealth Partners's MRKR Position: Q1 2023 in Review

Ascent Wealth Partners sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 1,027 shares — an estimated $2.73K sold.

Ascent Wealth Partners first reported a position in MRKR in Q2 2018 and held it in 17 quarters. The position peaked at $97K in Q2 2018. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

Ascent Wealth Partners reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
Ascent Wealth Partners sold 1,027 Marker Therapeutics shares in Q1 2023, an estimated $2.73K.
Ascent Wealth Partners first reported a position in Marker Therapeutics in Q2 2018 and held it in 17 quarters.
Ascent Wealth Partners's Marker Therapeutics position peaked at $97K in Q2 2018.
30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Ascent Wealth Partners's 13F filing for Q1 2023, filed 25 Apr 2023.